Sarsasapogenin‐AA13 ameliorates Aβ‐induced cognitive deficits via improving neuroglial capacity on Aβ clearance and antiinflammation

• Published in: CNS neuroscience & therapeutics 2017-06, Vol.23 (6), p.498-509
• Main Authors: Huang, Cui, Dong, Dong, Jiao, Qian, Pan, Hui, Ma, Lei, Wang, Rui
• Format: Article
• Language: English
• Subjects: Amyloid beta-Peptides - toxicity; Analysis of Variance; Animals; Animals, Newborn; antiinflammation; beta‐amyloid clearance; Cells, Cultured; Cerebral Cortex - cytology; Cognition Disorders - chemically induced; Cognition Disorders - drug therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Intraventricular; Male; Maze Learning - drug effects; Mice; Mice, Inbred ICR; neuroglia; Neuroglia - drug effects; Neuroglia - physiology; Original; Peptide Fragments - toxicity; phagocytosis; Phagocytosis - drug effects; sarsasapogenin‐AA13; Spirostans - chemistry; Spirostans - therapeutic use; Time Factors
• ISSN: 1755-5930; 1755-5949
• DOI: 10.1111/cns.12697

Summary Aims Sarsasapogenin has been reported to improve dementia symptoms somehow, probably through modulating the function of cholinergic system, suppressing neurofibrillary tangles, and inhibiting inflammation. However, the role of sarsasapogenin in response to beta‐amyloid (Aβ) remains to be delineated. This study aimed to determine the therapeutic effect of sarsasapogenin‐13 (AA13, a sarsasapogenin derivative) on learning and memory impairments in Aβ‐injected mice, as well as the role of AA13 in neuroglia‐mediated antiinflammation and Aβ clearance. Methods Focusing on the role of AA13 in regulating glial responses to Aβ, we conducted behavioral, morphological, and protein expression studies to explore the effects of AA13 on Aβ clearance and inflammatory regulation. Results The results indicated that oral administration of AA13 attenuated the memory deficits of intracerebroventricular (i.c.v.) Aβ‐injected mice; also, AA13 protected neuroglial cells against Aβ‐induced cytotoxicity. The further mechanical studies demonstrated that AA13 reversed the upregulation of proinflammatory M1 markers and increased the expression of antiinflammatory M2 markers in Aβ‐treated cells. Furthermore, AA13 facilitated Aβ clearance through promoting Aβ phagocytosis and degradation. AA13 modulated the expression of fatty acid translocase (CD36), insulin‐degrading enzyme (IDE), neprilysin (NEP), and endothelin‐converting enzyme (ECE) in neuroglia. Conclusion The present study indicated that the neuroprotective effect of AA13 might relate to its modulatory effects on microglia activation state, phagocytic ability, and expression of Aβ‐degrading enzymes, which makes it a promising therapeutic agent in the early stage of Alzheimer's disease (AD).